T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ROC
151
DELISTED
ROCKWOOD HLDGS INC
ROC
| $788M | 0.17% |
10,366,414
-750,811
| -7% | -$55.2M |
|
152
Costco
COST
$417B
| $788M | 0.17% |
6,840,382
+370,572
| +6% | +$42.5M |
|
153
Harley-Davidson
HOG
$2.79B
| $778M | 0.17% |
11,145,255
-1,130,863
| -9% | -$79.7M |
|
|
HBI
154
DELISTED
Hanesbrands
HBI
| $777M | 0.17% |
31,570,080
+23,298,292
| +282% | +$481M |
|
155
Dentsply Sirona
XRAY
$2.32B
| $760M | 0.16% |
16,055,505
-2,569,342
| -14% | -$120M |
|
156
Mattel
MAT
$4.33B
| $759M | 0.16% |
19,467,887
+111,578
| +0.6% | +$4.33M |
|
157
Delta Air Lines
DAL
$59.6B
| $752M | 0.16% |
19,412,486
+930,500
| +5% | +$35.1M |
|
158
Ameriprise Financial
AMP
$49.9B
| $751M | 0.16% |
6,257,533
+198,861
| +3% | +$22.2M |
|
159
Vipshop
VIPS
$7.3B
| $749M | 0.16% |
39,889,300
+36,298,300
| +1,011% | +$582M |
|
160
Nike
NKE
$60.7B
| $744M | 0.16% |
19,176,426
+375,040
| +2% | +$14M |
|
161
Cardinal Health
CAH
$55.7B
| $732M | 0.16% |
10,673,083
+686,277
| +7% | +$46.7M |
|
162
Fidelity National Financial
FNF
$13B
| $722M | 0.16% |
40,124,571
-150,099
| -0.4% | -$2.81M |
|
163
IBM
IBM
$225B
| $721M | 0.16% |
4,159,335
-97,231
| -2% | -$17.5M |
|
|
CPN
164
DELISTED
Calpine Corporation
CPN
| $716M | 0.15% |
30,052,837
+2,904,592
| +11% | +$65.9M |
|
165
Allstate
ALL
$67.7B
| $713M | 0.15% |
12,136,458
-8,308,832
| -41% | -$479M |
|
|
AVP
166
DELISTED
Avon Products, Inc.
AVP
| $709M | 0.15% |
48,521,219
+2,073,943
| +4% | +$29.9M |
|
167
Fastenal
FAST
$60.5B
| $709M | 0.15% |
57,283,876
-17,915,864
| -24% | -$222M |
|
|
N
168
DELISTED
Netsuite Inc
N
| $706M | 0.15% |
8,131,469
+3,626,528
| +81% | +$293M |
|
|
PCYC
169
DELISTED
PHARMACYCLICS INC
PCYC
| $695M | 0.15% |
7,751,307
+1,048,516
| +16% | +$98.4M |
|
170
Emerson Electric
EMR
$90.7B
| $693M | 0.15% |
10,438,978
+30,365
| +0.3% | +$2.04M |
|
|
TRW
171
DELISTED
TRW AUTOMOTIVE HOLDINGS CORP
TRW
| $690M | 0.15% |
7,709,248
-1,031,638
| -12% | -$86.1M |
|
172
AbbVie
ABBV
$439B
| $672M | 0.15% |
11,908,085
+2,886,871
| +32% | +$151M |
|
173
Duke Energy
DUK
$95.8B
| $670M | 0.14% |
9,029,355
-122,960
| -1% | -$8.84M |
|
174
Southwest Airlines
LUV
$22.4B
| $669M | 0.14% |
24,906,185
-4,451,890
| -15% | -$112M |
|
175
Franco-Nevada
FNV
$46.3B
| $668M | 0.14% |
11,609,983
+391,920
| +3% | +$19.1M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.